戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 hat dietary fat reduction would increase the relapse-free survival rate.
2 s, carboplatin was inferior because of lower relapse-free survival rates.
3 esponse, clinical deterioration, relapse and relapse-free survival rates.
4 ly associated with poor overall survival and relapse-free survival rates.
5                                     Two-year relapse-free survival rates (28% vs 39%, P = .843) and m
6  The median relapse-free survival and 1-year relapse-free survival rate are 7 months and 23%, respect
7 s, the 2-year estimated overall survival and relapse-free survival rates are 92% and 78%, respectivel
8 For patients who achieve a CR, the actuarial relapse-free survival rate at 5 years for PSCT patients
9 cimens were positive had significantly lower relapse-free survival rates at 36 months than patients w
10                                   The 3-year relapse-free survival rates for patients with positive a
11 a median follow-up of 4 years (IQR 3.0-4.9), relapse-free survival rates for radiotherapy and carbopl
12                               The 5-year PSA relapse-free survival rates for the 3D-CRT and the TPI g
13                                  Overall and relapse-free survival rates for the tacrolimus and CSP a
14 follow-up of 37 months, the actuarial 3-year relapse-free survival rate is 24% for the CC arm and 55%
15 er 3 months of NAAD experienced a 5-year PSA relapse-free survival rate of 74%, as compared with 40%
16                             The hema-tologic relapse-free survival rate of a subgroup of 9 patients w
17               The expression of VEGF and the relapse-free survival rate of breast cancer patients are
18                         The actuarial 3-year relapse-free survival rate was 30% (95% confidence inter
19    Among those who achieved a CR, the 5-year relapse-free survival rate was 43% in the DA+GO group an
20 ow-up of 24 months (range, 9-43), the 2-year relapse-free survival rate was 54% and the 2-year overal
21 sure closure of the study if the true 2-year relapse-free survival rate was 90% or lower.
22                                          The relapse-free survival rate was higher in the combined-tr
23 verall, disease-free, and distant metastatic relapse-free survival rates were 38.0%, 41.9%, and 56.0%
24 nse to pentostatin treatment, 5- and 10-year relapse-free survival rates were 85% (80%-91%) and 67% (
25                               The 5-year PSA relapse-free survival rates were 93%, 60%, and 40% for p
26                                    Five-year relapse-free survival rates were 94%, 78%, and 45%, resp